Global Eylea Market (By Disorder, Product, End User, Region), Company profiles and Market Dynamics – Forecast to 2030

The global Eylea market was valued at USD 9,714 Million in 2024, and is predicted to reach USD 14,545 Million by 2030. Eylea, also known as aflibercept, is a medication primarily used for the treatment of several eye disorders including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), diabetic retinopathy (DR), and macular edema following retinal vein occlusion (RVO). Eylea helps improve vision and reduce the risk of blindness in patients suffering from these retinal diseases. Since its regulatory approval over a decade ago, Eylea has redefined standards for retinal disease management by offering a potent anti-VEGF therapy with a consistent safety profile. Backed by robust clinical evidence, it has earned trust among ophthalmologists and patients alike, driving widespread adoption across key indications.

The growing aging population worldwide is expected to propel the growth of the Eylea market over the forecast period. With age-related eye conditions such as macular degeneration and diabetic retinopathy rising among older adults, demand for effective treatments such as Eylea is expected to grow. Furthermore, the major companies in the Eylea market are focusing on new product launches to expand the range of treatment options and meet the evolving needs of patients.

Key Highlights of the Report

Wet age-related macular degeneration (wet-AMD) dominated the Eylea market in 2024. Over 200 million people worldwide are affected by AMD, with projections estimating this number will increase to 300 million by 2040 due to the aging global population.

The market for Diabetic macular edema is driven by the rising prevalence of diabetes due to unhealthy lifestyle, increased awareness, and advancements in treatment options. Around 21 million people globally are affected by diabetic macular edema.

The Myopic choroidal neovascularization (mCNV) segment held low double-digit share of the total Eylea market in 2024, driven by rising myopia prevalence, especially in East Asia along with improved diagnosis, early screening, and favourable reimbursement in countries like Japan and South Korea.

Based on product type, the prefilled syringes (PFS) captured highest share of the overall Eylea market in 2024. The prefilled syringes industry is experiencing significant regional expansion, as manufacturers are increasingly setting up production facilities in emerging markets to reduce costs and improve supply chain efficiency.

The vial package is popular owing to cost efficiency and standard intravitreal administration regimen compatibility, in geographies with less advanced healthcare infrastructure. Additionally, in markets where cost constraints are critical, the vial format remains more economical.

Hospitals are the dominant end-user segment in the Eylea market, maintaining a strong lead due to their well-developed ophthalmic care centers. This is largely possible because of their established infrastructure, which includes specialized eye care units, experienced retinal specialists, and on-site pharmacy services, creating an ideal setting for patients to receive intravitreal medication such as Eylea.

Retail pharmacies are an emerging end-user segment in the global Eylea market, driven by the changing healthcare delivery model that promotes decentralized care, increased patient need for convenient access to treatment, and the growing use of prefilled syringes, which is a format optimally adapted for pharmacy-based dispensing.

North America dominated the Eylea market in 2024, driven by robust healthcare infrastructure, supportive reimbursement policies, and rising awareness of anti-vascular endothelial growth factor (anti-VEGF) therapy.

Europe captured nearly a quarter share of the Eylea market in 2024, driven by strong healthcare infrastructure, greater utilization of advanced therapeutics, and favorable reimbursement systems in nations such as Germany, France, and the United Kingdom.

Asia Pacific is showing significant growth opportunities in the Eylea market. The key factors shaping Eylea uptake in the region include the surging incidence of diabetic macular edema (DME) and other retinal diseases which are linked to rising diabetes prevalence and ageing demographics across the region.

Apelo Consulting report titled “Global Eylea Market (By Disorder, Product, End User, Region), Company profiles and Market Dynamics – Forecast to 2030” provides a complete assessment of the fast–evolving, high–growth Global Eylea Market landscape.

This 77 Pages report with 35 Figures and 8 Tables has been analyzed from 8 pointers:

1) Global - Eylea Market and Forecast (2021 – 2030)

2) Global - Eylea Market Share and Forecast (2021 – 2030)

3) By Disorder – Global Eylea Market and Forecast (2021 – 2030)

4) By Product – Global Eylea Market and Forecast (2021 – 2030)

5) By End-user – Global Eylea Market and Forecast (2021 – 2030)

6) By Region –Eylea Market and Forecast (2021 – 2030)

7) Global Eylea Market & Forecast – Company Profiles

8) Global Eylea Market – Market Dynamics

Global Eylea Market and Forecast – By Disorder

1. Wet Age-related macular degeneration (AMD)

2. Diabetic Macular Edema

3. Diabetic Retinopathy

4. Retinal Vein Occlusion

5. Myopic Choroidal Neovascularization

6. Others

Global Eylea Market and Forecast – By Product

Prefilled Syringe Package

Vial Package

Global Eylea Market and Forecast – By End user

Hospitals

Retail pharmacy

Others

Global Eylea Market and Forecast – By Region

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Data Source

Apelo Consulting employs comprehensive primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by Apelo Consulting dedicated team of qualified professionals with deep industry experience and expertise. Show more